InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (7 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
7
T+90 hit rate
33%
T+90 mean return
-1.9%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Brynjelsen Sean, Chief Executive Officer. Director active across 1 company, notably Eton Pharmaceuticals, Inc.. Cumulatively, 14 reports have been logged. Breakdown: 3 buys · 7 sells. Total volume traded: €9.5m. Activity tracked since 3 June 2021. The latest transaction was disclosed on 19 August 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Brynjelsen Sean
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
8,978 shares@ US$62.65Common StockSEC:0001437749-26-028651:0
47,307 shares@ US$60.17Common StockSEC:0001437749-26-028651:1
36,373 shares@ US$61.11Common StockSEC:0001437749-26-028651:2
7,342 shares@ US$62.12Common StockSEC:0001437749-26-028651:3
200,000 shares@ US$1.370.016% mcap5.1% of flowCommon StockSEC:0001437749-26-023570:1
27,500 sharesCommon StockSEC:0001437749-26-023570:0
119,852 shares@ US$31.880.21% mcap87.4% of flowCommon StockSEC:0001437749-26-018879:0
148 shares@ US$32.670.0003% mcap0.1% of flowCommon StockSEC:0001437749-26-018879:1
5,015 shares@ US$15.390.0042% mcap14.7% of flowCommon StockSEC:0001437749-26-001290:0
6,732 shares@ US$16.830.0062% mcap21.6% of flowCommon StockSEC:0001437749-25-037741:0
60,945 shares@ US$17.3820.8% of flowCommon StockSEC:0001437749-25-019583:0
10,000 shares@ US$2.10420.6% of flowCommon StockSEC:0001493152-22-026629:0
Canonical exit: 21 Dec 2022 (T+90)
10,000 shares@ US$4.320.8% of flowCommon StockSEC:0001493152-21-020807:0
Canonical exit: 18 Nov 2021 (T+90)
5,000 shares@ US$5.960.5% of flowCommon StockSEC:0001493152-21-013513:0
Canonical exit: 1 Sept 2021 (T+90)
14 of 14 declarations
About Brynjelsen Sean
BRYNJELSEN SEAN is Directeur Général and also holds the role of President & CEO at Eton Pharmaceuticals, Inc. The 10 filings recorded span from 2021-06-03 to 2026-07-14 in the recent filings tracked, with EUR 82,939 of buys and EUR 4,224,354 of sells, and the most frequent transaction nature is sale.
